Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 5—May 2011

Dispatch

Probable Non–Vector-borne Transmission of Zika Virus, Colorado, USA

Brian D. FoyComments to Author , Kevin C. Kobylinski, Joy L. Chilson Foy, Bradley J. Blitvich, Amelia Travassos da Rosa, Andrew D. Haddow, Robert S. Lanciotti, and Robert B. Tesh
Author affiliations: Author affiliations: Colorado State University, Fort Collins, Colorado, USA (B.D. Foy, K.C. Kobylinski); Poudre Valley Hospital, Fort Collins (J.L.C. Foy); Iowa State University, Ames, Iowa, USA (B.J. Blitvich); University of Texas Medical Branch, Galveston, Texas, USA (A. Travassos da Rosa, A.D. Haddow, R.B. Tesh); Centers for Disease Control and Prevention, Fort Collins (R.S. Lanciotti)

Main Article

Table A1

Serologic results for 3 patients in whom symptoms of arboviral illness developed, northern Colorado, USA, 2008*

Serum sample Viruses/viral antigens tested
GETV CHIKV SINV ZIKV DENV1 DENV2 DENV3 DENV4 YFV WNV UGSV SLEV TAHV JCV LACV
Hemagglutination inhibition test
Pt1a 0 0 NT 5,120 2,560 640 2,560 2,560 5,120 2,560 1,280 NT 0 NT NT
Pt1c 0 0 NT 5,120 1,280 320 1,280 1,280 2,560 1,280 1,280 NT 0 NT NT
Pt2a 0 0 NT 1,280 160 80 320 320 1,280 160 160 NT 0 NT NT
Pt2c 0 0 NT 2,560 160 80 320 320 1,280 160 160 NT 0 NT NT
Pt3a 0 0 NT 0 0 0 0 0 0 0 0 NT 0 NT NT
Pt3c
0
0
NT
320
0
0
0
0
0
0
0
NT
0
NT
NT
Plaque-reduction neutralization test
Pt1a NT <10 <10 10,240 80 1,280 320 160 >20,480 <10 NT 80 <10 NT NT
Pt1c NT NT NT >40,960 160 230 320 320 >40,960 160 NT NT NT NT NT
Pt2a NT NT NT 10,240 <20 80 80 40 5,120 NT NT NT NT NT NT
Pt2c NT NT NT 40,960 80 160 160 160 20,480 80 NT NT NT NT NT
Pt3a NT NT NT 10 <10 <10 <10 <10 <10 <10 NT <10 NT <10 <10
Pt3c
NT
NT
NT
1,280
<10
<10
<10
<10
<10
<10
NT
NT
NT
NT
NT
Complement fixation test
Pt1a NT NT NT 64/8 NT NT NT NT 64/8 NT NT NT NT NT NT
Pt1c NT NT NT 128/32 NT NT NT NT 64/8 NT NT NT NT NT NT
Pt2a NT NT NT 16/8 NT NT NT NT 16/8 NT NT NT NT NT NT
Pt2c NT NT NT 32/32 NT NT NT NT 16/8 NT NT NT NT NT NT
Pt3a NT NT NT 0 NT NT NT NT 0 NT NT NT NT NT NT
Pt3c NT NT NT 16/8 NT NT NT NT 0 NT NT NT NT NT NT

*Togaviridae: GETV, Getah virus; CHIKV, chikungunya virus; SINV, Sindbis virus; Flaviviridae: ZIK, Zika virus; DENV, dengue virus; YFV, yellow fever virus; WNV, West Nile virus; UGSV, Uganda S virus; SLEV, St. Louis encephalitis virus; Bunyaviridae: TAHV, Tahyna virus; JCV, Jamestown Canyon virus; LAC, La Crosse virus; pt1, 2, and 3, patients 1, 2, and 3, respectively; a and c, acute-phase and convalescent-phase serum samples, respectively; NT, not tested. Hemagglutination test, numbers are reciprocal of serum dilution inhibiting 4 units of antigen; 0 = negative reaction at a 1:20 dilution. Plaque-reduction neutralization test, numbers refer to neutralizing antibody titers with a 90% cutoff value: titers > positive control serum samples are indicated in boldface. Complement fixation tests, numbers refer to reciprocal of serum titer/reciprocal of antigen titer; 0, negative reaction at <8/<8.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO